Knoll Capital Management’s Krystal Biotech KRYS Stock Holding History

Knoll Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-120,212	Closed	-$4.17M	–	21
2019 Q3	$4.17M	Sell	120,212 -26,878	-18%	-$1.2M	3.82%	6
2019 Q2	$5.92M	Sell	147,090 -62,896	-30%	-$2.06M	4.85%	5
2019 Q1	$6.91M	Sell	209,986 -90,014	-30%	-$2.12M	5.25%	4
2018 Q4	$6.23M	Hold	300,000	–	–	7.09%	4
2018 Q3	$5.1M	Hold	300,000	–	–	4.31%	6
2018 Q2	$4.46M	Hold	300,000	–	–	3.79%	6
2018 Q1	$3.03M	Hold	300,000	–	–	3.11%	5
2017 Q4	$3.16M	Hold	300,000	–	–	2.78%	6
2017 Q3	$2.99M	Buy	+300,000	New	+$3.02M	2.56%	6

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Knoll Capital Management's KRYS Position: Q4 2019 in Review

Knoll Capital Management sold out of Krystal Biotech (KRYS) in Q4 2019, closing a stake of 120,212 shares — an estimated $4.17M sold.

Knoll Capital Management first reported a position in KRYS in Q3 2017 and held it in 9 quarters. The position peaked at $6.91M in Q1 2019. 90 funds tracked by Wall St. Rank hold KRYS as of Q4 2019.

Knoll Capital Management reported no remaining Krystal Biotech position as of Q4 2019 after selling out during the quarter.
Knoll Capital Management sold 120,212 Krystal Biotech shares in Q4 2019, an estimated $4.17M.
Knoll Capital Management first reported a position in Krystal Biotech in Q3 2017 and held it in 9 quarters.
Knoll Capital Management's Krystal Biotech position peaked at $6.91M in Q1 2019.
90 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2019.

Based on Knoll Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.